Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children - Trial NCT05091008
Access comprehensive clinical trial information for NCT05091008 through Pure Global AI's free database. This Phase 2 trial is sponsored by Mansoura University Children Hospital and is currently Completed. The study focuses on Hepatitis C, Chronic. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mansoura University Children Hospital
Timeline & Enrollment
Phase 2
Mar 01, 2018
Mar 10, 2020
Primary Outcome
Evaluate the efficacy of Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), in children with treatment-Naïve, chronic HCV infection, genotype 4.,Evaluate the efficacy of Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), in children with treatment-Naïve, chronic HCV infection, genotype 4.
Summary
Chronic hepatitis C virus (HCV) infection represents a crucial health problem in children
 that greatly influence their quality of life. Many efforts have been directed toward the
 investment of effective drugs with high safety profiles and with oral administration for
 better compliance. The development of a new direct-acting antiviral (DAA) made it possible to
 achieve these goals.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05091008
Non-Device Trial